Bufexamac
Bufexamac is a selective IIb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with Kds of 0.53 µM and 0.22 µM for HDAC6 and HDAC10. Bufexamac is a nonsteroida anti-inflammatory drug[1][2][3].
Product Specifications
CAS Number
2438-72-4
Product Name Alternative
Bufexamic acid
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Aminopeptidase; HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bufexamac.html
Purity
98.0
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL
Smiles
O=C(NO)CC1=CC=C(OCCCC)C=C1
Molecular Formula
C12H17NO3
Molecular Weight
223.27
Precautions
H302, H312, H332
References & Citations
[1]Bantscheff M, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29 (3) :255-65.|[2]Oehme I, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A. 2013 Jul 9;110 (28) :E2592-601.|[3]Xiao Q, et al. Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. |[4]Schölz C, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015 Apr;33 (4) :415-23.|[5]Suominen MM, et al. Effects of intra-articular injections of bufexamac suspension in healthy horses. Am J Vet Res. 2001 Oct;62 (10) :1629-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HDAC10; HDAC3; HDAC6; HDAC8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
